Soprano@Soprano

3Sem.

Have you read up on who the stuff is actually intended for and who the most important target groups of "prep" are?

Afficher l'original (Allemand)

J'aime••Réponse

Tenbagger2024@Tenbagger2024

3Sem.

@Soprano
The company has a large pipeline, so not just the one drug.
I took a look at the estimates.
Earnings per share go up from 4.39 to 7.48.
Free cash flow from 9397.86 to 10433.23
EbiT margin from 29 to 43
Turnover continues to rise.
The P/E ratio falls to 13

Afficher l'original (Allemand)

J'aime•

👍

11

•Réponse

DerJude@DerJude

2Sem.

@Tenbagger2024 I've been in it myself since €59.26 😊

Afficher l'original (Allemand)

J'aime••Réponse

Tenbagger2024@Tenbagger2024

2Sem.

@Ni485
Cool my dear,
Fundamentally, it doesn't look too bad.

Afficher l'original (Allemand)

J'aime••Réponse